



Bereskin & Parr



Receipt #4

Barristers and Solicitors/Patent and Trade Mark Agents
Practice Restricted to Intellectual Property Law

January 15, 2002

Micheline Gravelle B.Sc., M.Sc. (Immunol.)
416 957 1682 mgravelle@bereskinparr.com

Your Reference: 09/933,131
Our Reference: 10723-26

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231
U.S.A.

Dear Sir:

Re: REQUEST FOR CORRECTED FILING RECEIPT
Re: U.S. Regular Patent Application No. 09/933,131
Filed: August 21, 2001
Title: METHOD OF MODULATING TUMOR IMMUNITY
Inventors: Li Zhang and Kevin Young

RECEIVED
JAN 24 2002
TECH CENTER 1600/2900

Enclosed is a photocopy of the Updated Filing Receipt received from the United States Patent and Trademark Office for the above-identified patent application. The Updated Filing Receipt is erroneous in that there are two provisional priority applications indicated. Please delete application 60/226,160 filed August 16, 2000 from the Domestic Priority data, as it was not claimed in the above-noted application.

Correction of the records of the United States Patent and Trademark Office and issuance of a corrected Filing Receipt are hereby respectfully requested. The Commissioner is hereby authorized to charge any fees which may be required to our Deposit Account No. 02-2095.

Respectfully submitted,

Li Zhang and Kevin Young

Micheline Gravelle
Registration No. 40,261
BERESKIN & PARR

MG/db
Encl.



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/933,131	08/21/2001	1646	435	10723-26	7	11	3

CONFIRMATION NO. 4949

UPDATED FILING RECEIPT



OC000000007230428

MICHELINE & GRAVELLE
Bereskin & Parr
Box 401
40 King Street West
Toronto, ON M5H 3Y2
CANADA

Date Mailed: 12/26/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Li Zhang, Toronto, CANADA;
Kevin Young, Toronto, CANADA;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/226,573 08/21/2000
~~AND CLAIMS BENEFIT OF 60/226,160 08/10/2000~~ delete

Foreign Applications

If Required, Foreign Filing License Granted 10/03/2001

Projected Publication Date: 04/04/2002

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Method of modulating tumor immunity

Preliminary Class

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



UNITED STATES PATENT AND TRADEMARK OFFICE

FILE COPY

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov


Bib Data Sheet

CONFIRMATION NO. 4949

SERIAL NUMBER 09/933,131	FILING DATE 08/21/2001 RULE	CLASS 424	GROUP ART UNIT 1642	ATTORNEY DOCKET NO. 10723-26
APPLICANTS Li Zhang, Toronto, CANADA; Kevin Young, Toronto, CANADA;				
** CONTINUING DATA ***** THIS APPLN CLAIMS BENEFIT OF 60/226,573 08/21/2000				
** FOREIGN APPLICATIONS *****				
IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** SMALL ENTITY ** ** 10/03/2001				
Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance Verified and Acknowledged _____ Examiner's Signature _____ Initials _____		STATE OR COUNTRY CANADA	SHEETS DRAWING 7	TOTAL CLAIMS 11
				INDEPENDENT CLAIMS 3
ADDRESS <div style="text-align: right;">AIR MAIL</div> MICHELINE & GRAVELLE Bereskin & Parr Box 401 40 King Street West Toronto ,ON M5H 3Y2 CANADA				
TITLE Method of modulating tumor immunity				
FILING FEE RECEIVED 435	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	

 RECEIVED
 JAN 24 2002
 TECH CENTER 1600/2900